Related Experiment Video
Updated: Aug 27, 2025

Identification of Kinase-substrate Pairs Using High Throughput Screening
Published on: August 29, 2015
Inferring kinase activity from phosphoproteomic data: Tool comparison and recent applications
Sander R Piersma1, Andrea Valles-Marti1, Frank Rolfs1
1OncoProteomics Laboratory Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
Abstract:
Aberrant cellular signaling pathways are a hallmark of cancer and other diseases. One of the most important signaling mechanisms involves protein phosphorylation/dephosphorylation. Protein phosphorylation is catalyzed by protein kinases, and over 530 protein kinases have been identified in the human genome. Aberrant kinase activity is one of the drivers of tumorigenesis and cancer progression and results in altered phosphorylation abundance of downstream substrates. Upstream kinase activity can be inferred from the global collection of phosphorylated substrates. Mass spectrometry-based phosphoproteomic experiments nowadays routinely allow identification and quantitation of >10k phosphosites per biological sample. This substrate phosphorylation footprint can be used to infer upstream kinase activities using tools like Kinase Substrate Enrichment Analysis (KSEA), Posttranslational Modification Substrate Enrichment Analysis (PTM-SEA), and Integrative Inferred Kinase Activity Analysis (INKA). Since the topic of kinase activity inference is very active with many new approaches reported in the past 3 years, we would like to give an overview of the field. In this review, an inventory of kinase activity inference tools, their underlying algorithms, statistical frameworks, kinase-substrate databases, and user-friendliness is presented. The most widely-used tools are compared in-depth. Subsequently, recent applications of the tools are described focusing on clinical tissues and hematological samples. Two main application areas for kinase activity inference tools can be discerned. (1) Maximal biological insights can be obtained from large data sets with group comparisons using multiple complementary tools (e.g., PTM-SEA and KSEA or INKA). (2) In the oncology context where personalized treatment requires analysis of single samples, INKA for example, has emerged as tool that can prioritize actionable kinases for targeted inhibition.
Insights
This review overviews tools for inferring kinase activity from phosphoproteomics data. These methods help understand disease signaling and guide personalized cancer treatments by identifying key kinases.
Area of Science:
- Biochemistry and Molecular Biology
- Cancer Research
- Bioinformatics
Background:
- Aberrant cellular signaling, particularly protein phosphorylation, drives cancer and other diseases.
- Protein kinases regulate phosphorylation; their dysregulation is a key factor in tumorigenesis.
- Phosphoproteomic data from mass spectrometry can reveal upstream kinase activity.
Purpose of the Study:
- To provide a comprehensive overview of tools for inferring kinase activity from phosphoproteomic data.
- To compare algorithms, statistical frameworks, and usability of existing kinase activity inference tools.
- To highlight recent applications in clinical and hematological samples.
Main Methods:
- Review and inventory of kinase activity inference tools.
- Analysis of underlying algorithms, statistical frameworks, and kinase-substrate databases.
- In-depth comparison of widely-used tools and recent applications.
Main Results:
- Identified and inventoried various kinase activity inference tools (e.g., KSEA, PTM-SEA, INKA).
- Compared tools based on algorithms, statistics, databases, and user-friendliness.
- Demonstrated applications in clinical tissues and hematological samples for both group comparisons and single-sample analysis.
Conclusions:
- Kinase activity inference tools are crucial for understanding disease mechanisms and developing targeted therapies.
- Complementary tools (e.g., PTM-SEA, KSEA, INKA) maximize insights from large datasets.
- INKA shows promise for prioritizing actionable kinases in personalized oncology.

